Despite treatment with intensive immunosuppressive drug regimens, the prognosis of @entity1 suffering from severe progressive @entity792 like @entity1252 ( @entity1252 ), @entity1985 ( @entity1985 ), and Beh  et's disease is poor. Side effects (infections and @entity5 ) often occur. In the present trial, 35 @entity1 suffering from @entity792 ( @entity1252 , n = 21; @entity1985 , n = 10; and Beh  et's disease, n = 4) were treated for 3.7 +/- 2.0 years with 2.5 +/- 0.6 mg @entity205 /kg body weight/day in addition to corticosteroids alone or in combination with @entity500 and/or @entity786 . In active stages of the diseases with extremely high concentrations of anti-ds-DNA-antibodies, antinuclear antibodies, circulating immunocomplexes, and reduced complement concentrations, therapeutic plasma exchange (TPE) has been applied. Compared with previous treatment modalities, significantly (p < 0.05) more effective and rapid reductions of the antibodies were reached. Clinical disorders improved within 1-6 weeks. All @entity1 reported increased performance and a better quality of life. After 1-12 months, the previously required doses of immunosuppressive drugs and the frequency of TPE could be reduced by 40-100%. After 13.4 +/- 11.8 months in 17 of 35 @entity1 (8 with @entity1252 , 5 with @entity1985 , 4 with Beh  et's disease), @entity205 was established as the monotherapy. No severe side effects were registered. In treating active stages of severe progressive @entity792 and forms with persistent high antibody levels, the addition of TPE to conventional therapy was very effective, as observed in both clinical and laboratory parameters.

@entity205 and therapeutic plasma exchange in treatment of progressive XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant tumors'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine'] @entity1985 :: ('MESH:D009404', 'Disease') :: ['NS', 'nephrotic syndrome'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune diseases']
@entity792 :: (MESH:D001327,Disease) :: ['autoimmune diseases']
